Related Experiment Video

Updated: Aug 10, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Congenital and neurological abnormalities in infants with phenylketonuria

C F Johnson, R Koch, R M Peterson

    American Journal of Mental Deficiency
    |January 1, 1978
    PubMed

    Insights

    Children with phenylketonuria (PKU) treated with a restricted phenylalanine diet showed no major neurological defects. Congenital anomalies occurred at rates similar to the general population, with a possible increase in pyloric stenosis.

    Area of Science:

    • Medical Genetics
    • Pediatric Neurology
    • Metabolic Disorders

    Background:

    • Phenylketonuria (PKU) is a rare genetic disorder requiring dietary management.
    • Early diagnosis and treatment are crucial for preventing neurological complications in PKU patients.
    • Longitudinal studies are essential to assess the long-term outcomes of PKU treatment.

    Purpose of the Study:

    • To evaluate the occurrence of congenital and neurological abnormalities in children with PKU treated with a restricted phenylalanine diet.
    • To compare the incidence of anomalies in PKU patients with the general population.
    • To assess the effectiveness of dietary intervention in preventing neurological deficits.

    Main Methods:

    • Analysis of data from a nation-wide longitudinal collaborative study.
    • Inclusion of 150 children with PKU, aged 1 year or older, on a restricted phenylalanine diet.
    • Assessment of congenital anomalies and neurological status.

    Main Results:

    • The overall occurrence of congenital anomalies was 9.3%, not significantly different from the general population.
    • An apparent increased incidence of pyloric stenosis was observed in the PKU cohort.
    • No persistent major neurological defects were found in any of the studied subjects.

    Conclusions:

    • Dietary management of phenylketonuria (PKU) appears effective in preventing major neurological deficits.
    • Congenital anomaly rates in treated PKU children are comparable to the general population, barring pyloric stenosis.
    • Continued monitoring and research are warranted for PKU management and outcomes.

    More Related Videos

    A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy10:02

    A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

    Published on: November 3, 2016

    A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations08:22

    A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

    Published on: December 1, 2017

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Overview of Protein Metabolism01:21

    Overview of Protein Metabolism

    Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
    Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...